ArticleEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2019
Platelet-rich plasma as an additional therapeutic option for infected wounds with multi-drug resistant bacteria: in vitro antibacterial activity study.
Article in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials.Scientific reports · 2024Pooled it
- Systematic literature review evaluating evidence and mechanisms of action for platelet-rich plasma as an antibacterial agent.Journal of cardiothoracic surgery · 2021Pooled it
- Risk prediction of encephalitis in hand, foot and mouth disease: a nomogram model based on platelet indices for resource-limited settings.Italian journal of pediatrics · 2026Article
- Article
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Antibacterial and antibiofilm activity of platelet-rich plasma under different activation conditions against multidrug-resistant MRSA isolated from human skin abscesses.BMC biotechnology · 2025Article
- Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections.Scientific reports · 2025Article
- Platelet concentrates in diabetic foot ulcers: A comparative review of PRP, PRF, and CGF with case insights.Regenerative therapy · 2025Article
- Consensus on the Diagnosis and Treatment of Adult Necrotizing Fasciitis (2025 Edition).Burns & trauma · 2025Article
- Progress in the clinical application of allogeneic platelet-rich plasma for diabetic foot treatment.Frontiers in endocrinology · 2025Review
- Comparative analysis of cytokine profiles in canine injectable platelet-rich fibrin and platelet-rich plasma.International journal of veterinary science and medicine · 2025Article
- Antibacterial Effect of Canine Leucocyte Platelet-Rich Plasma (L-PRP) and Canine Platelet-Poor Plasma (PPP) Against Methicillin-Sensitive and Methicillin-ResistantVeterinary sciences · 2024Article
- Platelet-rich fibrin in the management of oral mucosal lesions: a scoping review.BMC oral health · 2024Article
- An In Vitro Study on the Application of Silver-Doped Platelet-Rich Plasma in the Prevention of Post-Implant-Associated Infections.International journal of molecular sciences · 2024Article
- The Potential of Sheep or Camel Milk Constituents to Contribute to Novel Dressings for Diabetic Wounds.International journal of molecular sciences · 2023Review
- Platelet- Rich Plasma Treatment Supported by Ultrasound Detection of Septa in Recurrent Canine Aural Hematoma: A Case Series.Animals : an open access journal from MDPI · 2023Article
- A review of platelet-rich plasma for enteric fistula management.Frontiers in bioengineering and biotechnology · 2023Review
- Effect of Platelet-Rich Plasma Augmentation on Endoscopy-Assisted Percutaneous Achilles Tendon Repair.Journal of clinical medicine · 2022Article
- Use of Intravesical Injections of Platelet-Rich Plasma for the Treatment of Bladder Pain Syndrome: A Comprehensive Literature Review.Antibiotics (Basel, Switzerland) · 2021Review
- An evaluation of the bacteriostatic effect of platelet-rich plasma.International wound journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInfected wounds, such as diabetic foot infections, are mostly polymicrobial and microorganisms have high resistance rates to antimicrobials. Infected wounds in diabetic patients have high cost, morbidity, and mortality rates. Based on these facts, there is a need for supportive localized treatment options such as platelet-rich plasma (PRP) implementations. Demonstrating the in vitro antimicrobial effect, our aim was to lead up to clinical trials of localized PRP implementations in infected wounds such as diabetic foot infections. In this study, we aimed to demonstrate the in vitro antibacterial activity of PRP against methicilin-resistant Staphylococcus aureus (MRSA) and three more multi-drug resistant bacteria species that are important and hard-to-treat in wound infections. MATERIALS AND
methodsIn vitro antimicrobial activity of autologous PRP, platelet-poor plasma (PPP), and phosphate-buffered saline (PBS) on methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., extended spectrum beta lactamase producing Klebsiella pneumoniae, and carbapenem-resistant Pseudomonas aeruginosa was compared by assessment of bacterial growth on agar plates and antimicrobial susceptibility test results.
resultsWhen compared to control group, PRP and PPP significantly suppressed bacterial growth of MRSA, K. pneumoniae, and P. aeruginosa at 1st, 2nd, 5th, and 10th hours of incubation (p < 0.05). VRE was the only bacteria that PRP and PPP showed limited activity against. When compared to PPP, PRP showed higher activity against MRSA, K. pneumoniae, and P. aeruginosa. However, the differences between PRP and PPP were statistically significant only against MRSA and P. aeruginosa at the first hour of incubation.
conclusionsEmerging PRP and other platelet-derived products seem to be promising alternative tools besides antibiotic treatment, debridement, negative pressure wound therapy, hyperbaric oxygen therapy, and other treatment options for treating diabetic foot infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.